Sax Wealth Advisors LLC Has $292,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Sax Wealth Advisors LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 17.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,995 shares of the biopharmaceutical company’s stock after acquiring an additional 1,630 shares during the period. Sax Wealth Advisors LLC’s holdings in Pfizer were worth $292,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Gladius Capital Management LP increased its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP acquired a new stake in Pfizer during the second quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer during the 3rd quarter worth $35,000. Joseph Group Capital Management raised its holdings in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares in the last quarter. Finally, Kennebec Savings Bank bought a new stake in shares of Pfizer during the 3rd quarter valued at $50,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.7 %

PFE opened at $26.30 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company’s 50 day moving average price is $26.08 and its two-hundred day moving average price is $27.99. The firm has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.17) earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of analyst reports. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim reduced their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.